V Kongu je umrlo več kot 400 ljudi zaradi ebole, Svetovna zdravstvena organizacija pa je napovedala začetek kliničnega preskušanja
An outbreak of Ebola in the Democratic Republic of Congo (DRC) has resulted in over 400 deaths, according to the latest report released on July 2. The epidemic, which began on May 15 and is caused by the Bundibugyo virus, continues to spread, with a recent confirmed case in Kisangani, a major city in the northeast. There is currently no vaccine or treatment available for this strain of Ebola. The World Health Organization (WHO) has launched a clinical trial to develop a potential treatment, marking a significant step in the response efforts. As of now, 438 deaths and 1,406 cases have been reported, resulting in a fatality rate of 31.2%. The outbreak is primarily concentrated in the Ituri province, bordering South Sudan and Uganda, and nearby regions in North and South Kivu. While no new cases have been reported in Uganda since June 21, a case of Marburg fever, similar to Ebola, was detected. The DRC president emphasized the need for cross-border health cooperation, highlighting the importance of international support amid declining aid. A recent UNDP report estimates the outbreak could cost up to $3.6 billion across Africa.
Ob nadaljnjem izbruhu ebole v Demokratični republiki Kongo (DRC) je Svetovna zdravstvena organizacija (WHO) začela s kliničnim preskušanjem, katerega cilj je razvoj učinkovitih zdravil za sev virusa Bundibugyo. To je pomemben korak v svetovnem boju proti eboli, saj za ta posebni variant ne obstaja nobeno posebno cepivo ali zdravljenje. Preskušanje, ki je bilo objavljeno 2. julija 2026, vključuje oceno dveh potencialnih terapevtskih možnosti - monoklonskega protitela MBP134 in protivirusnega zdravila remdesivir - tako posamično kot v kombinaciji.
Ta pobuda prihaja v času naraščajoče zaskrbljenosti zaradi širjenja virusa, saj je bilo do zdaj zabeleženih 1.406 potrjenih primerov in 438 smrtnih primerov, kar pomeni, da je stopnja smrtnosti približno 31 odstotkov.
Študija se je začela z vpisom prvega bolnika, kot je povedal generalni direktor WHO Tedros Adhanom Ghebreyesus med tiskovno konferenco. Študija namerava oceniti učinkovitost teh zdravljenj s naključno razdelitvijo udeležencev v štiri skupine: tiste, ki prejemajo remdesivir, tiste, ki prejemajo MBP134, tiste, ki ne prejemajo niti enega, in tiste, ki prejemajo oba. Število bolnikov, potrebnih za dokončne rezultate, je odvisno od učinkovitosti terapij, ocene pa kažejo, da bi preskušanje lahko vključevalo več kot 1000 posameznikov.
Vasee Moorthy, vodja raziskovalnega in razvojnega načrta Svetovne zdravstvene organizacije, je dejal, da se pričakuje, da bo preskušanje trajalo več mesecev in se lahko razširi do naslednjega leta.
Tedros je poudaril, da izbruh še naprej narašča, saj je v zadnjih dveh tednih na dan poročanih v povprečju 38 novih primerov. Kljub izboljšavam pri sledenju na stike, pri čemer se spremljajo štirje od petih stikov, je identifikacija dodatnih stikov še vedno nujno vprašanje.
Trenutno je v 22 zdravstvenih centrih na voljo 650 postelj, skoraj vse so zasedene, v prihodnje pa je predvidenih dodatnih 300 postelj.
WHO je poročala o nasilnih dogodkih, ki so vplivali na odziv. Nedavno je bilo središče za zdravljenje ebole v Ituriju napadeno, kar je privedlo do smrti dveh posameznikov in prisililo bolnike, da so pobegnili. Takšni napadi ne ogrožajo le življenja bolnikov in zdravstvenih delavcev, temveč tudi ovirajo obvladovanje izbruha.
Predsednik Demokratične republike Kongo Felix Tshisekedi je na tiskovni konferenci ob južnoafriškem predsedniku Cyrilu Ramaphosi poudaril strateško potrebo po transnacionalnih zdravstvenih partnerstvih.
Pojav izbruha ebole sovpada s širšimi izzivi, s katerimi se srečujejo nevladne organizacije zaradi zmanjševanja mednarodne pomoči. Poleg tega odkrivanje primera virusa Marburg v Ugandi dodaja še eno sloj zapletenosti na področju javnega zdravja.
The World Health Organization announced the start of a clinical trial for two potential treatments for the Bundibugyo strain of Ebola in the Democratic Republic of Congo (DRC). The trial involves the monoclonal antibody MBP134 and the antiviral drug remdesivir, testing them individually and in combination. As of the latest data, there have been 1,406 confirmed cases and 438 confirmed deaths, with 208 recoveries. The trial will begin in Ituri province and may require over 1,000 participants, potentially lasting several months. WHO officials emphasized the importance of ensuring access to effective treatments post-trial. The outbreak faces challenges including limited treatment capacity and ongoing conflicts in the region.
Ocena pristranskosti (Sredina): The article presents factual information about a medical trial without overtly favoring any political ideology. While the subject matter relates to public health policy, the framing remains neutral, focusing on scientific progress and humanitarian efforts rather than partisan agendas. The emphasis,措
Zakaj te ocene (Dejstva 98 · Objektivnost 95): Highly factual with specific details on the trial, including names of treatments and methodology. Presents information objectively without emotional language. Consistent with other sources on case numbers and WHO actions.
France 24 (Français)Državni / javniSredinaDejstva 95Objektivnost 88včeraj
An outbreak of Ebola in the Democratic Republic of Congo (DRC) has resulted in over 400 deaths, according to the latest report released on July 2. The epidemic, which began on May 15 and is caused by the Bundibugyo virus, continues to spread, with a recent confirmed case in Kisangani, a major city in the northeast. There is currently no vaccine or treatment available for this strain of Ebola. The World Health Organization (WHO) has launched a clinical trial to develop a potential treatment, marking a significant step in the response efforts. As of now, 438 deaths and 1,406 cases have been reported, resulting in a fatality rate of 31.2%. The outbreak is primarily concentrated in the Ituri province, bordering South Sudan and Uganda, and nearby regions in North and South Kivu. While no new cases have been reported in Uganda since June 21, a case of Marburg fever, similar to Ebola, was detected. The DRC president emphasized the need for cross-border health cooperation, highlighting the importance of international support amid declining aid. A recent UNDP report estimates the outbreak could cost up to $3.6 billion across Africa.
Ocena pristranskosti (Sredina): The article presents factual information about the Ebola outbreak and the WHO's response without overtly favoring any political stance. It includes quotes from officials and reports from international organizations but does not take a clear ideological position. The emphasis is on the medical and vi
Zakaj te ocene (Dejstva 95 · Objektivnost 88): Factual accuracy is high, reporting confirmed case numbers and the WHO's response. The article presents information neutrally but includes some emotionally charged descriptions of the epidemic's impact. Cross-source consensus supports the reported statistics.
France 24 (English)Državni / javniSredinaDejstva 0Objektivnost 0pred 15 urami
Članek se zdi video segment iz France 24, ki je bil namenjen zagotavljanju pokritosti o začetku preskušanja zdravljenja ebole v Demokratični republiki Kongo (DRC), kot je poročala Svetovna zdravstvena organizacija (WHO).
Ocena pristranskosti (Sredina): Vsebina se nanaša na pobude javnega zdravja in mednarodne zdravstvene organizacije, ki se na splošno štejejo za nizko sporne teme. Medtem ko vključitev SZO kaže na določeno raven vladnega ali institucionalnega nadzora, ni znakov za očitno ideološko oblikovanje.
Zakaj te ocene (Dejstva 0 · Objektivnost 0): No content available to assess factuality or objectivity. The video embed is non-functional and provides no substantive information.
★
Ohranimo novice poštene.
ObjectiveNews financirajo bralci in je brez oglasov – pristranskost vam pokažemo, ne skrijemo. Podprite neodvisno novinarstvo za 5 €/mesec.
France
